Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EBT (2018 - 2025)

Arcturus Therapeutics Holdings' EBT history spans 8 years, with the latest figure at -$29.1 million for Q4 2025.

  • For Q4 2025, EBT rose 3.09% year-over-year to -$29.1 million; the TTM value through Dec 2025 reached -$65.8 million, up 18.73%, while the annual FY2025 figure was -$65.8 million, 18.73% up from the prior year.
  • EBT reached -$29.1 million in Q4 2025 per ARCT's latest filing, down from -$13.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $118.6 million in Q4 2022 to a low of -$57.7 million in Q1 2021.
  • Average EBT over 5 years is -$18.3 million, with a median of -$24.0 million recorded in 2022.
  • Peak YoY movement for EBT: crashed 509.45% in 2021, then skyrocketed 415.16% in 2022.
  • A 5-year view of EBT shows it stood at -$37.6 million in 2021, then surged by 415.16% to $118.6 million in 2022, then tumbled by 109.65% to -$11.4 million in 2023, then crashed by 162.2% to -$30.0 million in 2024, then rose by 3.09% to -$29.1 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's EBT are -$29.1 million (Q4 2025), -$13.4 million (Q3 2025), and -$9.2 million (Q2 2025).